A multicenter randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of rhubarb in treating acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs  by Zheng, Fengjie et al.
Journal of Traditional Chinese Medical Sciences (2016) 3, 71e80Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.elsevier.com/locate / j tcmsA multicenter randomized, double-blind,
placebo-controlled trial to evaluate the
safety and efficacy of rhubarb in treating
acute exacerbation of chronic obstructive
pulmonary disease of the syndrome type
phlegm-heat obstructing the lungs
Fengjie Zheng, Yan Sun, Xianggen Zhong, Yueqi Wang,
Ruohan Wu, Miao Liu, Yuchao Liu, Kuo Gao, Yuhang Li*School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, ChinaReceived 24 June 2016; accepted 1 July 2016
Available online 6 July 2016KEYWORDS
Traditional Chinese
medicine;
COPD;
Phlegm-heat
obstructing the lung
syndrome;
Rhubarb;
Randomized
controlled trialAbbreviations: COPD, chronic obstruc
obstructive pulmonary disease; FVC, f
forced vital capacity ratio; FAS, full
obstructive lung disease; RT, routine
interleukin 4.
* Corresponding author.
E-mail address: liyuhang@bucm.ed
Peer review under responsibility o
http://dx.doi.org/10.1016/j.jtcms.20
2095-7548/ª 2016 Beijing University o
CC BY-NC-ND license (http://creativeAbstract Objective: To observe the clinical efficacy and safety of oral administration of the
traditional Chinese herb rhubarb to treat acute exacerbation of chronic obstructive pulmonary
disease (AECOPD).
Method: This was a multicenter randomized double-blinded placebo controlled study that took
place in 7 provinces of China that enrolled 244 patients (aged 18e80 years) who had acute
exacerbation of COPD with the traditional Chinese syndrome pattern of phlegm-heat obstruct-
ing lung. Participants were divided into experimental and control groups. The experimental
group received 4.5 g of rhubarb granules twice daily and the control group received placebo
granules. Both groups also received conventional Western therapy consisting of oxygen ther-
apy, an antibiotic, expectorant, and a bronchodilator. Treatment lasted 10 days. Symptom
scores for cough, sputum volume and color, wheezing and chest tightness before treatment
and on days 3, 5, 7, and 10 during the treatment were recorded. Lung function, arterial blood
gas and levels of serum inflammatory factors, interleukin-4 (IL-4), interleukin-8 (IL-8), andtive pulmonary disease; TCM, traditional Chinese medicine; AECOPD, acute exacerbation of chronic
orced vital capacity; FEV1, forced expiratory volume in 1 s; FEV1%, forced expiratory volume in 1 s/
analysis set; PPS, per protocol set; CRP, C reactive protein; GOLD, global initiative for chronic
test; ECG, electrocardiogram; ABG, arterial blood gas; TNF-a, tumor necrosis factor alpha; IL-4,
u.cn (Y. Li).
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were measured.
Results: The sample size of the full analysis set (FAS) was 244 participants, and the sample size
of per protocol set (PPS) was 235. Following 10 days’ treatment, symptom scores of the exper-
imental group were markedly lower than those of the placebo group (FAS: mean difference
1.67, 95% CI: e2.66 to 0.69, P Z 0.001; PPS: mean difference 1.55, 95% CI: 2.56 to
0.54, P Z 0.003). Lung function in the experimental group was significantly higher than in
the placebo group (FEV1, FAS: mean difference 0.12, 95% CI: 0.06 to 0.18; P < 0.001; PPS: mean
difference 0.12, 95% CI 0.05 to 0.18; P < 0.001. FVC: FAS: mean difference 0.16, 95% CI: 0.06 to
0.26; PZ 0.002; PPS: mean difference 0.16, 95% CI 0.05 to 0.26; PZ 0.003. FEV1%, FAS: mean
difference 5.95, 95% CI: 3.36 to 8.53; P < 0.001; PPS: mean difference 5.92, 95% CI 3.28 to
8.56; P < 0.001.). PaO2, PaCO2, as well as serum inflammatory factors were also improved
when compared to the placebo group. There were no significant differences in the incidence
rate of adverse reaction between the two groups.
Conclusions: Compared with placebo, rhubarb granules significantly reduced symptom scores,
improved blood oxygen level, controlled systemic inflammatory response, without significant
adverse effects. Thus, rhubarb may be a beneficial adjuvant method for treating the
phlegm-heat obstructing the lung syndrome pattern of AECOPD.
ª 2016 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is a world-
wide chronic respiratory disease that seriously impairs
health. The Golbal Burden of Disease Study projected that
COPD, which ranked sixth as a cause of death in 1990, will
become the third leading cause of death worldwide by
2020; a newer projection estimated COPD will be the fourth
leading cause of death in 2030.1 A 2010 large-scale epide-
miologic survey showed that the prevalence of COPD in
China is higher than that in developed countries, and this is
likely to increase significantly.2
The hallmark symptoms of COPD are dyspnea, cough,
and increased amounts of phlegm and/or purulent phlegm
exceeding the daily variation that require a change in drug
therapy. Patients with COPD will have acute exacerbations
about 0.5e3.5 times annually.3,4 Acute exacerbation of
chronic obstructive pulmonary disease (AECOPD) results in
massive healthcare expenditures. Furthermore, morbidity
and mortality from AECOPD is high. Rapid relief of symp-
toms, reducing the accelerating decline in lung function
and quality of life caused by frequent attacks are the
therapeutic targets for AECOPD.5e7 Although symptoms in
50% of patients with AECOPD recover to baseline in 7 days,
in 14% of patients, symptoms and reduced lung function can
persist for 35 days, which typically induces or aggravates
cardiovascular complications.8e10
Both drug and non-drug therapies are available for the
treatment of AECOPD. Short-acting bronchodilators, corti-
costeroids, and antimicrobials among others are common
agents. Non-drug approaches include reducing exposure to
risk factors, home oxygen therapy, lung volume reduction
surgery, and mechanical ventilation. However, these
methods are only partially effective at controlling acuteexacerbations and continuing decline of lung function.11
Therefore, preventing attacks and controlling symptoms
of AECOPD are urgent areas of research.
Syndrome pattern differentiation is a unique feature of
traditional Chinese medicine (TCM). Once a pattern of
symptoms has been identified, treatment is instituted
based on the pattern. One type of lung disorder pattern is
called phlegm-heat. Its symptoms include cough, dyspnea,
fever, and throat pain. The TCM etiology is accumulation of
phlegm, which transforms into heat, resulting in phlegm-
heat blockage of the lungs. Treatment principle is to use
herbal prescriptions that have purging actions.
Clinical trials have validated that Chinese herbal com-
pounds can relieve COPD symptoms, reduce frequency of
AECOPD, and improve quality of life.12e14 Our previously
published randomized double-blind controlled study, of
which this study was a part of, showed that the herbal
formula Xuan Bai Cheng Qi formula can reduce the symp-
toms of phlegm-heat obstruction pattern of COPD,
decrease AECOPD frequency, improve ventilatory disorders,
and lower serum cytokine levels. Results indicated that
based on the TCM theory the lung and the large intestine
being interior-exteriorly related, treating the lung and
large intestine simultaneously can effectively manage
AECOPD.15 In the formula, rhubarb (Rheum palmatum L.) is
the main herbal ingredient whose action is to clear the
stomach and intestines. In a study by Li et al, rhubarb and
conventional Western medications were used at an early
stage to treat AECOPD (phlegm-heat obstructing the lung
syndrome) with apparent efficacy. However, their sample
size was small and only a single case-control study test
index was used.16 Thus, we undertook this multicenter
randomized double-blind, placebo-controlled trial to assess
the efficacy and safety of rhubarb for phlegm-heat
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principle of treating the large intestine also treats the
lungs.
Methods
Ethics and trial registration
This study was approved by ethical research committees of
Dongzhimen Hospital affiliated to Beijing University of
Chinese Medicine (No. DZMSP20090302). This study was part
of a larger trial registered with the Chinese Clinical Trial
Registry Center (ChiCTR-TRC-09000533).
Study design and participants
This was a multicenter randomized double-blind, placebo-
controlled clinical trial. Male and female patients aged
18e80 years with COPD, diagnosed from October 2009 to
February 2013, were enrolled.
The sample size was calculated by the method of
approximate sample size. Basing on comparable studies,
suppose the effective rate of convertional medicine plus
placebo was 75%, and the effective rate of convertional
medicine combined with rhubarb was 90%.16,17 The control
group and trial group adoped 1:1 parallel design. With 5%
one-side significance level and 90% statistical power, it was
determined that 122 participants should be randomly
assigned to each group, considering an approximate 10%
drop-out rate. Overall, we studied 244 cases.
Randomization and blinding
SAS 8.0 software (SAS Institute, Cary, NC, USA) was used to
generate 1e244 randomized numbers and a data table to
randomize drug allocation and drug numbers. Patients who
met the inclusion criteria and signed the informed consent
form were randomly allocated to the treatment group or
control group. Participants and investigators, including
statisticians, were blinded to the identity of the experi-
mental medicine and placebo. Unblinded envelopes were
prepared at the same time to ensure physicians had access
to the therapeutic measures administered to patients in
case of an emergency.
Diagnostic criteria
Diagnoses of COPD and AECOPD were based on the Global
Initiative for Chronic Obstructive Lung Disease (GOLD;
2007)18 criteria and on Chinese Society of Respiratory Dis-
eases (2007) guidelines.19
Phlegm-heat obstructing the lung syndrome was diag-
nosed based on State Administration of Traditional Chinese
Medicine guidelines20 and criteria outline by Wang and Lu.21
Primary symptoms included cough and/or wheezing,
yellow, sticky phlegm. Secondary symptoms included irri-
tability, thirst with desire for cold liquids, fever without
aversion to cold, yellow urine, hard stools, abdominalfullness, red tongue, yellow and greasy tongue coating, and
slippery pulse and rapid pulse.
COPD was diagnosed if primary symptoms existed com-
bined with any two or more of the secondary symptoms.
Inclusion and exclusion criteria
Patients were included if they met the diagnostic criteria of
AECOPD; had GOLD levels 1 through 4 symptoms; had an
acute attack of COPD within the past 5 days; were 18
through 80 years-old of either sex; were diagnosed with
TCM syndrome pattern of phlegm-heat obstructing the
lung; had not participated in other clinical trials within the
past 1 month; and provided informed consent.
Patients were excluded if they had airway limitation
caused by bronchiectasis, pulmonary cystic fibrosis, lung
cancer, or other respiratory disease; had COPD and
comorbidities such as heart failure, acute cerebral hem-
orrhage, digestive tract bleeding, aplastic anemia, acute
renal failure, or other severe disease; COPD with unstable
comorbidities such as hypertension, heart disease, dia-
betes; mental illness, severe neurologic deficit; severe
diseases of the heart, liver, kidney, and hemopoietic sys-
tem; recent use of immunosuppression agents; history of
allergy or known allergy to rhubarb or drugs used in the
trial; women who are pregnant or breastfeeding; and had
diarrhea or bowel movements 3 or more times a day.
Withdrawal criteria
Withdrawal from the trial included the following situations:
serious complications result from existing condition or
process or rapid deterioration of existing condition; devel-
opment of symptoms unrelated to existing condition that
affect participant’s completion of trial; poor adherence to
trial protocol; participant unwilling to continue in trial.
Treatment
Conventional therapy
Both the experimental and control groups received con-
ventional therapy, which was based on Chinese Society of
Respiratory Diseases (2007) guidelines19 and included
infection control with oxygen therapy (1e3 L/min) and
cefotaxime (2 g, intravenous gtt, Q12H); the expectorant
ambroxol hydrochloride (60e180 mg/d, BID), and the
bronchodilator aminophylline (200e300 mg/d, BID or TID).
Experimental and placebo treatments
The raw dried root and rhizome of rhubarb grown in
Liangzhou District, Gansu Province in China, and obtained
from Beijing Tong Ren Tang Pharmacy. The raw material
was then manufactured into boil-free granules (lot number:
0905301-3) by Jiangyin Tianjiang Pharmaceutical Company
(Jiangsu, China). This manufacturer also prepared the
placebo granules, which consisted of cyclodextrin, a bit-
tering agent, and food color. The rhubarb and placebo
granules had were of similar color and taste and were
administered at the same dosage: 9 g of granules (two
74 F. Zheng et al.packets, 4.5 g/packet) dissolved in hot water, 30 min after
breakfast and dinner, for 10 days. All participants were
instructed not to use any other herbal medicines during the
trial.Outcome measures
Primary outcomes
The primary outcome measures were symptom scores, lung
function, and safety index.
Symptom scores were determined based on a scale
similar to the Likert scale22 and on recommendations per
Zheng.23 Main symptoms of AECOPD, which are cough,
sputum volume and color, severity of wheezing and chest
tightness were scored on a scale of 0, 2, 4, and 6, which
represented, respectively, symptomatic, mild, moderate,
and severe,. Thus, the higher the score, the more severe
the symptoms. Scoring was completed independently by
investigators and participants before the trial started and
on days 3, 5, 7, and 10 (final day).
Lung function changes in the form of forced vital ca-
pacity (FVC), forced expiratory volume in 1 s (FEV1), and
FEV1 (% predicted) from baseline, measured on the day of
randomization and 10 days after randomization. FEV1 and
FVC were measured using calibrated spirometry on the day
of randomization before administration of the experi-
mental medicine and placebo. On day 10 after randomiza-
tion, FEV1 and FVC were measured after the morning dose.
Safety parameters included changes in routine blood and
urine test results, liver and kidney function test results,
changes in electrocardiogram, and type, severity, and
occurrence rate of adverse events.
Secondary outcomes
Secondary outcomes were arterial blood gas analysis and
inflammatory factor expression.
Arterial blood gas analysis included partial pressure of
carbon dioxide (PaCO2) and partial pressure of oxygen
(PaO2). Inflammatory factors assayed were tumor necrosis
factor alpha (TNFa), the cytokines, interleukins 4, 8, and 10
(IL4, IL8, IL10).Statistical analyses
Two researchers input the data using version 3.0 of Epidata
(Epidata Association, Odense, Denmark) to set up a data-
base. Analysis was performed against baseline information,
therapeutic evaluation, and safety index. The per-protocol
analysis set was used for participants who completed an
interview survey but withdrew halfway through the study
for various reasons. The last observation carried forward
(LOCF) was applied to partial loss of data information.
The paired-sample t-test or analysis of covariance was
used for continuous variable measurement data. The
HuynheFeldt (HeF) method was used for data that were
measured repeatedly on the same observational index at
different times. If HeF conditions were met, the data were
then analyzed as for repeated measurements. The chi
square test was used to test enumeration data. Therapeutic
effects were tested with 95% confidence interval. A value ofP < 0.05 was considered significant. All data were analyzed
with SPSS version 19.0.Results
Study population
Participants were recruited from October 2009 to February
2013 from 8 medical centers: Dongzhimen Hospital Affili-
ated to Beijing University of Chinese Medicine (38 partici-
pants), Dongfang Hospital of Beijing University of Chinese
Medicine (28 participants), Shuguang Hospital Affiliated to
Shanghai University of Traditional Chinese Medicine (38
participants), First Affiliated Hospital of Anhui University of
Chinese Medicine (26 participants), Chinese Medicine Hos-
pital of Hebei Province (40 participants), Affiliated Hospital
of Gansu University of Chinese Medicine (16 participants),
Affiliated Hospital of Liaoning University of Traditional
Chinese Medicine (42 participants), and Chinese Medicine
Hospital of Kaifeng City of Henan Province (16
participants).
At the outset, 285 patients were screened and evalu-
ated, 41 patients were excluded, thus 244 participants
were randomized (Fig. 1). Intention-to-treat analysis
resulted in 122 allocated to the experimental group, and
the remaining 122 participants in the placebo group. All 244
cases were included in the analysis. During the trial, 3
participants dropped out without explanation, 1 participant
from the experimental group and participants from the
placebo group. For participants who withdrew, data
observed at the last time point was included in the analysis.
All 244 participants completed baseline screening, and
there was no statistical difference in demographic data
(age, sex, height, and weight), vital signs (blood pressure
and heart rate), disease duration, and symptom scores
between groups (P > 0.05), indicating baseline data of the 2
groups were similar (Table 1).Primary outcomes
There were no significant differences in main symptom
(cough, expectoration, wheezing, and chest tightness)
scores between the 2 groups at baseline before treatment
(Table 2). On days 3, 5, 7, and 10 of treatment, main
symptoms scores in the experimental group were signifi-
cantly lower than those in the placebo group (Table 2).
There were no significant differences in FEV1, FVC, and
FEV1% between the 2 groups at baseline before treatment
(Table 3). After the end of treatment (on day 10), FEV1,
FEV, and FEV1% were significantly higher in the experi-
mental group compared with the placebo group (Table 3).
Blood, urine RT, and liver and kidney function test results,
as well as ECG assessments of the 2 groups were not
significantly different before and after treatment (Table 4).
Serious adverse reactions were not observed in either
group. Two participants in the placebo group and seven
participants in the experimental group developed diarrhea
that was not statistically significant.
Assessed for eligibility (n = 285) 
Excluded (n = 41) 
  Did not meet inclusion 
    criteria (n = 18) 
  Refused to parƟcipate (n = 20) 
  Other reasons (n = 3) 
Assigned to the trial group (n = 122) 
 Rhubarb granules and convenƟonal 
therapy  
Assigned to the control group (n = 122) 
Placebo and convenƟonal therapy 
Completed the study (n = 120) 
Full analysis set (n = 122) 
Per-protocol analysis set (n = 117) 
Had protocol noncompliance (n = 3) 
Withdrew without explanaƟon (n = 1) 
Randomized paƟents (n = 244) 
(8 centers) 
Completed the study (n = 121) 
Full analysis set (n = 122) 
Per-protocol analysis set (n = 118) 
Had protocol noncompliance (n = 2) 
Used other drugs (n = 1) 
Withdrew without explanaƟon (n = 2) 
Fig. 1 Trial profile.
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PaCO2 and PaO2 did not differ significantly between the 2
groups at baseline before treatment (Table 5). However, at
the end of treatment on day 10, PaCO2 in the experimental
group was significantly lower than that in the placebo group
(Table 5), and PaO2 was significantly higher than that in the
placebo group. When attempting to collect blood samples
for inflammatory factor analyses, only 20 serum samples
were collected from the treatment group, and 17 were
collected from the placebo group. At baseline, there were
no significant differences in the levels of TNF-a, IL4, IL8,
and IL10 between the 2 groups (Table 6). At the end of
treatment on day 10, levels of TNF-a, IL8, and IL-4 were
significantly lower in the experimental group than in the
placebo group. However, IL10 levels were significantly
higher in the experimental group than in the placebo group
(Table 6).Discussion
TCM theory holds that the lung and the large intestine are
interior-exteriorly related. The lung and large intestine are
connected through their channels, and the two organs are
thus physiologically interrelated, and affect one another
pathologically. For example, patients with allergic rhinitis
(upper respiratory system) and asthma (lungs) had more
lower gastrointestinal symptoms compared with patients
with diabetes, osteoarthritis, rheumatoid arthritis.24Digestive system manifestations, such as gastroesophageal
reflux, gastrointestinal mucosal barrier dysfunction, slow
gastrointestinal motility, abdominal distension, con-
stipation, among other symptoms are usually during
AECOPD.25,26 Our previous study showed that symptoms of
the lower digestive tract, such as constipation and
abdominal distension, can have a negative impact on pul-
monary symptoms, induce AECOPD, and reduce quality of
life.27 Therefore, in treating COPD, it is important to ensure
the intestinal tract remains unobstructed in patients with
lower digestive tract symptoms of constipation and
abdominal distension. Maintaining an unobstructed gut is a
common TCM treatment for constipation of excess heat
pattern. In China, Major Order the Qi Decoction (da cheng
qi tang), a representative prescription for clearing the gut,
is often modified for treatment of the phlegm-heat
obstructing the lung pattern of COPD. A systematic review
reported that treating patients who have frequent AECOPD
with modifications of this formula appears to improve
FEV1%, reduce arterial PCO2, and shorten duration of me-
chanical ventilation. However, large-sample RCTs vali-
dating these findings are lacking.28
Rhubarb is a Chinese herb that has been used for cen-
turies to treat intestinal obstruction. The active chemical
compounds in this herb are emodin, chrysophanic acid,
rhein, and anthraquinone glycoside.29e33 These compounds
have antipyretic, anti-inflammatory, anti-aging, antioxi-
dant, and immune regulatory effects, and are thus used
clinically for acute intestinal obstruction, chronic
nephrosis, acute pancreatitis among other disorders. The
Table 1 Baseline characteristics of participants.
Characteristics Trial group (n Z 122) Control group (n Z 122) t/X2/Z P
Age (SD), years 69.9  10.3 70.7  9.8 0.621 0.54
Body mass index (SD), kg/m2 23.2  3.4 22.8  3.1 1.09 0.28
Sex
Male, (n) % 84 (69%) 82 (67%) 0.08 0.78
Female, (n) % 38 (31%) 40 (33%)
Body temperature (C) 36.6  0.6 36.7  0.6 0.444 0.66
Exacerbation
Frequency (times) 2.5  1.2 2.6  1.2 0.575 0.57
Currently exacerbation 3.5  1.3 3.5  1.3 0.000 1
Smoking status
Currently smoking, n (%) 21 (17%) 16 (13%) 0.74 0.39
Never smoked, n (%) 47 (38%) 52 (42%)
Ever smoked, n (%) 54 (44%) 54 (44%)
No. of packs/years 326.3  210.9 337.9  192.6 0.07 0.95
FEV1/FVC 55.5  9.8 56.9  9.6 1.163 0.25
GOLD classification
GOLD 1, n (%) 9 (7%) 9 (7%) 1.37 0.24
GOLD 2, n (%) 62 (51%) 58 (48%)
GOLD 3, n (%) 37 (30%) 45 (37%)
GOLD 4, n (%) 14 (12%) 10 (8%)
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD,
Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation.
Table 2 Cumulative symptom scores in rhubarb and control groups during 10-day treatment.
Cumulative
symptom scores
Full analysis set Per-protocol analysis set
Rhubarb
groupa
(n Z 122)
Control
groupa
(n Z 122)
Treatment
effectb
(95% CI; P)
RR Rhubarb
groupa (n Z 117)
Control
groupa
(n Z 118)
Treatment effectb (95% CI; P-value)
Day1 (Baseline) 19.3 (4.5) 20.1 (4.3) 0.77 (1.88,
0.33; 0.17)
19.4 (4.5) 20.1 (4.3) 0.70 (1.84, 0.44; 0.23)
Day 3 14.3 (4.2) 16.5 (4.1) 2.16 (3.20,
1.11; <0.001)
14.3 (4.2) 16.4 (4.0) 2.09 (3.14, 1.04; <0.001)
Day 5 10.5 (3.6) 13.2 (4.2) 2.71 (3.68,
1.73; <0.001)
10.5 (3.6) 13.1 (4.1) 2.59 (3.58, 1.60; <0.001)
Day 7 8.0 (3.8) 9.6 (3.7) 1.67 (2.62,
0.73; 0.001)
8.1 (3.8) 9.5 (3.7) 1.46 (2.41, 0.50; 0.003)
Day 10 (End) 5.3 (4.1) 7.0 (3.7) 1.67 (2.66,
0.69; 0.001)
5.4 (4.1) 6.9 (3.7) 1.55 (2.56, 0.54; 0.003)
Abbreviation: CI, confidence interval.
Mauchly’s test of sphericity was applied: W Z 0.534, P < 0.001.
a Data presented as mean (SD).
b Repeated measures analysis of variance (ANOVA) for estimating with 95% confidence interval for difference.
76 F. Zheng et al.TCM action of rhubarb takes place primarily in the large
intestine, but by virtue of the relatedness of the large in-
testine and lung, symptoms of the lung, such as AECOPD,
can also be alleviated by rhubarb. Although these effects
are well-known in TCM and reported in the literature, there
are still no persuasive large-scale, evidence-based studies
of its safety and efficacy.
Our study was a randomized double-blinded placebo
controlled study that took place in 8 medical centers in 7
cities in China. By day 3 of receiving rhubarb and conven-
tional medicine, symptoms, including cough, amount ofsputum, wheezing, and chest tightness began to improve.
Arterial blood gas values also improved. The safety pa-
rameters measured in this study as well as the fact that no
adverse reactions occurred in either group, indicated that
rhubarb plus conventional therapy appears to be a safe
therapy.
COPD leads to systemic inflammatory responses
including oxidative stress, activation of inflammatory cells
in the peripheral blood and early generation of inflamma-
tory cytokines.34 Levels of IL4, IL8, TNF-a, and other in-
flammatory factors are higher in patients with AECOPD than
Table 3 Lung function measurements in rhubarb and control groups before and after 10-day treatment.
Lung function Full analysis set Per-protocol analysis set
Rhubarb groupa
(n Z 122)
Control groupa
(n Z 122)
Treatment effectc
(95% CI; P)
Rhubarb groupa
(n Z 117)
Control groupa
(n Z 118)
Treatment
effectc (95% CI; P)
FEV1 (liters)
Day 1 (Baseline) 1.19 (0.38)b 1.19 (0.40) 0.00 (0.10,
0.10; 0.97)
1.19 (0.38) 1.19 (0.39) 0.00
(0.09, 0.10; 0.93)
Day 10 (End) 1.41 (0.39) 1.29 (0.47) 0.12 (0.01,
0.23; 0.03)
1.42 (0.38) 1.29 (0.47) 0.12
(0.01, 0.23; 0.03)
Mean Db 0.22 (0.19) 0.10 (0.30) 0.12 (0.06,
0.18; <0.001)
0.22 (0.19) 0.10 (0.32) 0.12
(0.05, 0.18; <0.001)
FVC (liters)
Day 1 (Baseline) 2.18 (0.65) 2.10 (0.58) 0.08 (0.08,
0.23; 0.31)
2.19 (0.65) 2.11 (0.57) 0.08
(0.07, 0.24; 0.30)
Day 10 (End) 2.39 (0.53) 2.17 (0.62) 0.21 (0.07,
0.36; 0.004)
2.40 (0.51) 2.19 (0.60) 0.21
(0.07, 0.35; 0.005)
Mean Db 0.21 (0.42) 0.08 (0.48) 0.16 (0.06,
0.26; 0.002)
0.21 (0.42) 0.08 (0.48) 0.16
(0.05, 0.26; 0.003)
FEV1% Perd
Day 1 (Baseline) 53.48 (18.98) 52.13 (19.17) 1.35(3.46,
6.16; 0.58)
54.01 (18.84) 52.17 (19.27) 1.84
(3.06, 6.74; 0.46)
Day 10 (End) 62.49 (18.90) 55.35 (20.59) 7.14 (2.16,
12.12; 0.005)
63.10 (18.59) 55.56 (20.68) 7.54
(2.48, 12.59; 0.004)
Mean Db 9.01 (10.39) 3.22 (10.53) 5.95 (3.36.
8.53; <0.001)
9.09 (10.46) 3.39 (10.50) 5.92
(3.28, 8.56; <0.001)
Abbreviations: CI, confidence interval; FEV1%pred, FEV1 percentage of predicted value; FVC, forced vital capacity; Mean D, mean
difference.
a Data presented as mean (SD).
b P < 0.01: Change between pre-treatment and post-treatment (within group difference by paired t test).
c Covariance analysis estimate with 95% confidence interval (CI) for differences.
A multicenter randomized, double-blind, placebo-controlled trial 77in patients with stable COPD.35,36 Pathophysiology of COPD
involves interaction of numerous inflammatory cell types
leads to an imbalance of cellular immunity, promotes
appearance and development of COPD airway inflammation
and eventually leads to structural remodeling of the air-
ways and progressive airflow limitation.37e39 Our study
found significantly reduced levels of TNF-a and IL8 and
increased levels of IL10 in the experimental group
compared with the placebo group, indicating that rhubarb
may have helped regulate inflammatory cells and thus
control airway inflammation.Table 4 Safety profile.
Variablesa Rhubarb groupb (n Z 122)
Day 1 (Baseline) Day 10 (End)
WBC (109/L) 9.1 (4.7) 7.6 (3.2)
HB (g/L) 143.0 (29.2) 136.2 (26.8)
RBC (1012/L) 4.4 (0.7) 4.5 (1.1)
PLT (109/L) 212.4 (63.6) 210.9 (62.5)
NEUT (%) 66.5 (15.2) 61.8 (15.6)
ALT (U/L) 20.8 (13.5) 23.8 (11.6)
BUN (mmol/L) 6.1 (1.6) 5.8 (2.4)
Cr (umol/L) 79.5 (24.5) 77.1 (20.6)
Abbreviations: ALT, alanine aminotransferase; BUN, blood urea nitr
ulocytes; PLT, platelets; RBC, red blood cells; WBC, white blood cells
a Covariance analysis for between group after treatment.
b Data presented as mean (SD).However, there are some limitations to this study. First,
the duration of the study is only 10 days. Changes of pa-
tients’ quality of life and the frequency of acute exacer-
bations of COPD were not observable. In addition, it is
difficult to get blood samples, so the comparison between
levels of TNF-a, IL4, IL8, and IL10 are not from all enrolled
patients, which may therefore be biased. Further studies
should be performed to evaluate the long-term efficacy of
rhubarb formula as an adjuvant treatment for phlegm-heat
obstructing the lung syndrome pattern of AECOPD, andControl groupb (n Z 122) Pa
Day 1 (Baseline) Day 10 (End)
9.4 (8.0) 7.5 (3.1) 0.78
136.3 (28.1) 134.3 (28.1) 0.52
4.3 (0.6) 4.3 (0.6) 0.28
209.4 (76.9) 207.5 (68.4) 0.80
68.9 (14.9) 62.1 (13.4) 0.44
21.9 (16.3) 22.5 (14.1) 0.22
6.1 (2.8) 5.8 (2.8) 0.90
85.2 (46.5) 80.3 (35.9) 0.99
ogen; Cr, creatinine; HB, hemoglobin; NEUT, neutrophilic gran-
.
Table 5 Arterial blood gas analysis in rhubarb and control groups before and after 10-day treatment.
Variables Full analysis set Per-protocol analysis set
Rhubarb groupa
(n Z 122)
Control groupa
(n Z 122)
Treatment
effectc (95% CI; P)
Rhubarb
groupa
(n Z 117)
Control
groupa
(n Z 118)
Treatment effectc
(95% CI; P)
PaO2
Day 1 (Baseline) 70.6 (20.3) 71.5 (18.9) 0.86 (5.80,
4.08; 0.73)
70.3 (20.1) 71.3 (19.1) 0.93 (5.97, 4.11; 0.72)
Day 10 (End) 84.7 (20.4) 80.5 (15.9) 4.25 (0.36,
8.86; 0.07)
85.3 (20.6) 80.8 (16.0) 4.56 (0.16, 9.30; 0.06)
Improvement
from baseline
14.6 (24.2) 9.0 (17.5) 4.55 (0.26,
8.84; 0.04)
15.5 (23.8) 9.5 (17.3) 4.91 (0.55, 9.27; 0.03)
PaCO2
Day 1 (Baseline) 44.44 (9.9)b 46.2 (12.1) 1.77 (4.55,
1.01; 0.21)
44.0 (9.7) 45. 9 (11.8) 1.88 (4.66, 0.89; 0.18)
Day 10 (End) 38.2 (8.6) 41.5 (8.3) 3.26 (5.39,
1.13; 0.003)
38.0 (8.4) 41.4 (8.4) 3.39 (5.55, 1.23; 0.002)
Mean Db 6.3 (12.0) 4.8 (9.0) 2.67 (4.60,
0.74; 0.007)
6.0 (12.1) 4.5 (8.8) 2.78 (4.75, 0.80; 0.006)
Abbreviations:CI, confidence interval; PaO2, arterial partial pressure of oxygen; PaCO2, arterial partial carbon dioxide pressure; Mean D,
mean. difference.
a Data presented as mean (SD).
b P < 0.01: Change between pre-treatment and post-treatment (within group difference by paired t test).
c Covariance analysis estimate with 95% confidence interval (CI) for differences.
Table 6 Pro-inflammatory cytokine levels in rhubarb and control groups before and after 10-day treatment.
Biomarkers Rhubarb groupa Control groupa Treatment effectd
(95% CI; P-value)Day 1
(Baseline)
Day 10 (End) Mean Dc Day 1
(Baseline)
Day 10
(End)
Mean D
TNFa
(pg/mL)19 16
20.5 (3.4) 5.1 (1.9) 15.49 (4.39) 18.9 (3.6) 6.5 (1.6) 12.43 (3.28)c 1.41 (2.69, 0.14; 0.03)
IL4
(pg/mL)19 17
6.0 (1.8) 2.8 (1.4) 3.61 (1.78) 6.2 (1.4) 3.4 (1.3) 2.77 (1.70)c 0.98 (1.71, 0.24; 0.01)
IL8
(pg/mL)20 17
17.7 (3.3) 12.1 (3.1) 5.62 (4.31) 18.0 (4.2) 14.9 (3.9) 3.08 (5.36)b 2.81 (5.15, 0.46; 0.02)
IL10
(pg/mL)20 17
3.6 (0.8) 4.5 (1.1) 0.91 (1.22) 3.5 (0.7) 3.7 (1.0) 0.12 (1.21) 0.85 (0.12, 1,58; 0.02)
Abbreviations: CI, confidence interval; TNFa, tumor necrosis factor alpha; IL, interleukin; Mean D, mean difference.
a Data presented as mean (SD).
b P < 0.05.
c P < 0.01: Change between pre-treatment and post-treatment (within group difference by paired t test).
d Covariance analysis estimate with 95% confidence interval for differences.
78 F. Zheng et al.verify the inflammatory mechanism of rhubarb in the
treatment of AECOPD.Conclusion
We showed that oral administration of the granule form of
the Chinese herb rhubarb along with conventional therapy
helped treat phlegm-heat obstructing the lung syndrome
pattern of AECOPD and no significant side effects were
observed. The therapeutic mechanism of rhubarb may be
related to its ability to attenuate inflammation but further
studies are required to verify this.Funding
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